Purdue Pharma's $7 Billion Opioid Settlement Gains Momentum with All States' Support
All 50 U.S. states back Purdue Pharma's $7 billion opioid settlement, with a judge set to rule on allowing local governments and victims to vote on the agreement.
PBS NewsHourOxyContin maker Purdue Pharma asks court to clear way for $7 billion settlement if states back it
World News GroupAll 50 states agree to $7.4 billion Purdue Pharma settlement
Boston HeraldPurdue Pharma’s $7B opioid settlement could advance after states back it
ABC NewsJudge could advance Purdue Pharma's $7B opioid settlement after all 50 states back it
Overview
All 50 U.S. states have agreed to Purdue Pharma's $7 billion opioid settlement plan, moving it forward for court approval.
The Sackler family will relinquish ownership of Purdue Pharma as part of the settlement, paying up to $7 billion over 15 years.
A judge is expected to rule on whether local governments and individual victims can vote on the settlement agreement.
Most of the settlement funds will be allocated to state and local governments to combat the opioid addiction crisis, with some funds for individual victims.
The settlement aims to resolve lawsuits with claims exceeding $2 trillion, avoiding lengthy trials if approved by the court.
Analysis
Center-leaning sources frame the Purdue Pharma settlement as a significant legal resolution, emphasizing state consensus and potential victim compensation. They express cautious optimism about the settlement's impact on the opioid crisis while highlighting the complexities of legal proceedings and the financial stakes involved, reflecting a critical yet hopeful perspective.